Back

Phase 1 safety, tolerability, and pharmacokinetics of NS-863 supporting development for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease

31 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Pulmonary hypertension and right ventricular Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Yuichi Tamura

IUHW Mita Hospital, Tokyo (Japan)

4 More presentations in this session

Presentation thumbnail
Effects of high-intensity inspiratory muscle training on inspiratory muscle strength and exercise capacity in pulmonary arterial hypertension
Ms P. Wu (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
A CT echo triage model predicts markedly elevated pulmonary vascular resistance and right ventricular failure phenotype at catheterization
Doctor M. Al-Sarmi (Dublin, IE)
Abstract Slides Video
Presentation thumbnail
Beyond hypocapnia: standardised capillary oxygen partial pressure predicts risk and treatment response in PAH
Mr T. Kramer (Cologne, DE)
Abstract Slides Video
Presentation thumbnail
Diabetes is associated with reduced survival in controls but not in patients with idiopathic pulmonary arterial hypertension
Associate Professor B. Kjellstrom (Lund, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary hypertension and right ventricular

The Event

Event poster

ESC Congress 2026

31 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Session
Molecular approaches to the treatment of pulmonary hypertension
27 August 2023
thumbnail
Congress Presentation
PEDF upregulated in Ngfr-positive cells suppresses proliferation of pulmonary artery smooth muscle cells
31 August 2024
thumbnail
Congress Session
Daily Highlights Programme - Japanese Circulation Society
29 August 2022
thumbnail
Congress Presentation
Efficacy and safety of SYH2053 in patients with primary hypercholesterolemia or mixed dyslipidemia: a phase II, multicenter, randomized, double-blind, placebo- and active-controlled trial
31 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources